Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.

Abstract

Background Maraviroc (MVC) is a candidate drug for HIV preexposure prophylaxis (PrEP). Objective To assess the safety and tolerability of MVC-containing PrEP over 48 weeks in U.S. women at risk for HIV infection. Design Phase 2 randomized, controlled, double-blinded study of 4 antiretroviral regimens used as PrEP. (ClinicalTrials.gov: NCT01505114… (More)
DOI: 10.7326/M17-0520

Topics

Cite this paper

@article{Gulick2017SafetyAT, title={Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.}, author={Roy M. Gulick and Timothy J. Wilkin and Ying Q. Chen and Raphael J. Landovitz and Kathy Rivet Amico and Alicia M. Young and Paul G Richardson and Mark A. Marzinke and Craig W. Hendrix and Susan H Eshleman and Ian McGowan and Leslie M Cottle and Adriana Andrade and Cheryl Marcus and Karin L. Klingman and Wairimu Chege and Alex R. Rinehart and James F. Rooney and Philip Andrew and Robert A. Salata and Marc Siegel and Yukari C. Manabe and Ian Frank and Ken S Ho and Jorge L Santana and Joanne D Stekler and Shobha Swaminathan and Marybeth McCauley and Sally L Hodder and Kenneth H. Mayer}, journal={Annals of internal medicine}, year={2017}, volume={167 6}, pages={384-393} }